FDA proposes to withdraw Amgen's rare autoimmune disease drug
FDA proposes to withdraw Amgen's rare autoimmune disease drug
ReutersTue, April 28, 2026 at 1:04 AM UTC
0
The Amgen logo is seen in this illustration taken August 3, 2025. REUTERS/Dado Ruvic/Illustration
April 27 (Reuters) - The U.S. Food and Drug Administration's Center for Drug Evaluation and Research on Monday proposed withdrawing approval of Amgen's drug for a group of rare autoimmune diseases, citing a lack of proven effectiveness and untrue statements in the application that led to its approval.
Advertisement
In March, the FDA said it identified 76 cases of drug-induced liver injury with evidence suggesting a causal link to Tavneos, including seven cases of vanishing bile duct syndrome (VBDS), a rare condition that can cause permanent liver damage. Eight deaths were reported among those cases.
(Reporting by Natalia Bueno Rebolledo in Mexico City; Editing by Rashmi Aich)
Source: “AOL Breaking”
